Condition: Multiple Myeloma · Sponsor: Oncotherapeutics
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.
This description comes directly from the study's public registry record.
Richard Bailey · 310-464-2190 · rbailey@oncotherapeutics.com
Yohana Sebhat, MPH · 310-623-1222 · ysebhat@oncotherapeutics.com
Always discuss trial participation with your own doctor first.
| Berenson Cancer Center | West Hollywood, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06209606